Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA
Early clearance of ctDNA served as a predictive and prognostic marker in TNBC. Personalized ctDNA monitoring during NAC may help predict response and guide treatment.
Authors
- Salyna Meas (ORCID: https://orcid.org/0000-0001-5588-6337)
- Anil Korkut (ORCID: https://orcid.org/0000-0001-8072-9026)
- Banu Arun (ORCID: https://orcid.org/0000-0002-5475-8509)
- Jason B. White (ORCID: https://orcid.org/0000-0001-7140-545X)
- Dhruvajyoti Roy (ORCID: https://orcid.org/0000-0002-9202-6720)
- Roland L. Bassett (ORCID: https://orcid.org/0000-0002-4534-2042)
- Minetta C. Liu (ORCID: https://orcid.org/0000-0002-8206-5232)
- Gaiane M. Rauch
- Carlos H. Bárcenas (ORCID: https://orcid.org/0000-0001-5377-9167)
- Sridevi Addanki (ORCID: https://orcid.org/0000-0002-9224-3813)
- Stacy L. Moulder (ORCID: https://orcid.org/0009-0004-6078-2769)
- Anthony Lucci (ORCID: https://orcid.org/0000-0003-4039-174X)
- Clinton Yam (ORCID: https://orcid.org/0000-0002-0809-0851)
- Ekaterina Kalashnikova (ORCID: https://orcid.org/0000-0003-1078-0656)
- Himanshu Sethi (ORCID: https://orcid.org/0000-0002-5787-8901)
- Erik Spickard (ORCID: https://orcid.org/0000-0002-5024-3559)
- Vanessa Nicole Sarli
- Henry M. Kuerer
- Angel Rodriguez (ORCID: https://orcid.org/0000-0003-0735-3039)
- Jennifer Hechao Chen (ORCID: https://orcid.org/0000-0001-5281-3036)
- Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Eli Lilly (United States) (US)
- Natera (United States) (US)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1186/s12885-024-12689-6
- Citations
- 22
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Institutes of Health
- National Cancer Institute